Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease.

Longitudinal study leveraging a randomized trial

“In this longitudinal study of HIV-associated NAFLD, high rates of hepatic fibrosis and progression were observed.”

Participants with HIV-associated nonalcoholic fatty liver disease

“Sixty-one participants with HIV-associated NAFLD were randomized to tesamorelin or placebo for 12 months with serial biopsies.”

61 participants randomized, with 58 having baseline biopsies and 24 placebo-treated participants having paired biopsies

“Sixty-one participants with HIV-associated NAFLD were randomized to tesamorelin or placebo for 12 months with serial biopsies.”

12 months

“Sixty-one participants with HIV-associated NAFLD were randomized to tesamorelin or placebo for 12 months with serial biopsies.”

43% of participants with baseline biopsies had hepatic fibrosis

“In all participants with baseline biopsies (n = 58), 43% had hepatic fibrosis.”

38% of placebo-treated participants with paired biopsies experienced hepatic fibrosis progression over 12 months

“Among placebo-treated participants with paired biopsies (n = 24), 38% had hepatic fibrosis progression over 12 months.”

Higher baseline visceral fat was associated with increased odds of fibrosis progression

“For each 25 cm2 higher visceral fat at baseline, odds of fibrosis progression increased by 37% (odds ratio, 1.37 [95% confidence interval, 1.03–2.07]).”